Replay available

Mineralys Therapeutics, Inc. (MLYS) Q3 2025 Earnings Call

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) Q3 2025 earnings conference call, held 2025-11-10. Replay captured from the company's public earnings webcast.

Mon, November 10, 2025 at 4:30 PMendedReplay
Mineralys Therapeutics, Inc. (MLYS) Q3 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

John Cogleton

Chief Executive Officer

Dan Ferry

Host

Dr. David Rodman

Chief Medical Officer

Adam Levy

Chief Financial Officer

Uma Rapid

Evercore Analyst

Eric Warren

Chief Commercial Officer

Mohit Bansal

Wells Fargo Analyst

Rich Law

Goldman Sachs Analyst

Rami Kahuta

LifeSci Capital Analyst

Replay transcript excerpt

Greetings and welcome to Mineralis' third quarter's 2025 earnings conference call. At this time, all participants are on a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Dan Ferry. Thank you. You may begin. Thank you, operator. I would like to welcome everyone joining us today for our third quarter 2025 conference call. Earlier this afternoon, we issued a press release providing our third quarter 2025 financial results and business updates. A replay of today's call will be available on the investor section of our website, approximately one hour after its completion. After our prepared remarks, we will open the call for Q&A. Before we begin, I would like to remind everyone that this conference call webcast will contain forward-looking statements about the company. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified by the cautionary statements contained in today's press release and our SEC filings, including our annual report on Form 10-K and subsequent filings. Please note that these forward-looking statements reflect our opinions only as of today, November 10, 2025. Except as required by law, we specifically disclaim any obligation to update or revise these forward-looking statements in light of new information or future events. I would now like to turn the call over to John Cogleton, Chief Executive Officer of Mineralis Therapeutics. Thank...

More from Mineralys Therapeutics, Inc.